Efficacy of Sequential Treatment with Mouse Nerve Growth Factor Combined with Butylphthalide in Acute Cerebral Infarction
Objective To investigate the efficacy of sequential treatment with mouse nerve growth factor combined with butylphthalide in acute cerebral infarction.Methods Ninety patients with acute cerebral infarction admitted to The Fourth People's Hospital of Shangqiu from February 2020 to November 2022 were randomly divided into a control group(n=45)and an observation group(n=45).The control group received dual antiplatelet therapy,while the observation group received mouse nerve growth factor combined with butylphthalide sequential treatment in addition to the control group's medication.The degree of neurological deficit,activities of daily living,incidence of adverse reactions,clinical efficacy,thrombotic status indicators,and inflammatory response indicators were compared between the two groups.Results After treatment,the National Institutes of Health Stroke Scale(NIHSS)scores of both groups decreased,with the observation group scoring lower than the control group,showing statistically significant differences(P＜0.05).After treatment,the Barthel Index of Activities of Daily Living(ADL)in both groups increased,with the observation group scoring higher than the control group,showing statistically significant differences.The effective rate of treatment in the observation group(88.89%)was higher than that in the control group(66.67%),with statistically significant differences(P＜0.05).After treatment,the maximum platelet aggregation rate(MPAR),plasma D-dimer,and fibrinogen(FIB)levels in both groups decreased,with the observation group showing lower levels than the control group,with statistically significant differences(P＜0.05).After treatment,the serum oxidized low-density lipoprotein(ox-LDL)and soluble intercellular adhesion molecule-1(sICAM-1)levels in both groups decreased,while nitric oxide levels increased,with the observation group showing lower ox-LDL and sICAM-1 levels and higher nitric oxide levels than the control group,with statistically significant differences(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Sequential treatment with dual antiplatelet therapy combined with mouse nerve growth factor and butylphthalide is effective in treating acute cerebral infarction.It can effectively improve neurological deficit symptoms,thrombotic status,and reduce serum inflammatory factor levels without increasing adverse reactions.
acute cerebral infarctionbutylphthalidemouse nerve growth factoractivities of daily living
国家科技期刊平台
NSTL
万方数据
